Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven ...
stocknews3d
3 "Forever Stocks" You Can Buy and Hold for Decades
Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...
Santé log6d
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023. Net product sales of CAPLYTA were $199.2 million for the fourth quarter of ...
Medical Xpress2d
Major Depressive Disorder
The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status examination. There is no laboratory ...